The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.
Histologically or cytologically confirmed advanced solid tumors that have failed standard therapy or are intolerant to standard treatment.
According to RECIST 1.1 criteria, participants must have at least one target lesion.
ECOG performance status score of 0-1 with no deterioration within 2 weeks prior to the first dose.
Minimum expected survival greater than 12 weeks.
Patients with a contraindication for receiving itraconazole according to the prescribing information
Patients with severe, uncontrolled, or active cardiovascular diseases